Hubbry Logo
FosfomycinFosfomycinMain
Open search
Fosfomycin
Community hub
Fosfomycin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Fosfomycin
Fosfomycin
Fosfomycin
View on Wikipedia
from Wikipedia

Fosfomycin
Structural formula of fosfomycin
Ball-and-stick model of the fosfomycin molecule
Clinical data
Trade namesMonuril, Monurol, Ivozfo, others
Other namesPhosphomycin, phosphonomycin, fosfomycin tromethamine
AHFS/Drugs.comMonograph
MedlinePlusa697008
License data
Routes of
administration		Intravenous, By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability30–37% (by mouth, fosfomycin tromethamine); varies with food intake
Protein bindingNil
MetabolismNil
Elimination half-life5.7 hours (mean)
ExcretionKidney, unchanged
Identifiers
  • [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.041.315 Edit this at Wikidata
Chemical and physical data
FormulaC3H7O4P
Molar mass138.059 g·mol−1
3D model (JSmol)
Melting point94 °C (201 °F)
  • C[C@H]1[C@H](O1)P(=O)(O)O
  • InChI=1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1 checkY
  • Key:YMDXZJFXQJVXBF-STHAYSLISA-N checkY
  (verify)

Fosfomycin, sold under the brand name Monurol among others, is an antibiotic primarily used to treat lower urinary tract infections.[8] It is not indicated for kidney infections.[8] Occasionally it is used for prostate infections.[8] It is generally taken by mouth.[8]

Common side effects include diarrhea, nausea, headache, and vaginal yeast infections.[8] Severe side effects may include anaphylaxis and Clostridioides difficile-associated diarrhea.[8] While use during pregnancy has not been found to be harmful, such use is not recommended.[9] A single dose when breastfeeding appears safe.[9] Fosfomycin works by interfering with the production of the bacterial cell wall.[8]

Fosfomycin was discovered in 1969 and approved for medical use in the United States in 1996 [globalize][8][10] It is on the World Health Organization's List of Essential Medicines.[11] The World Health Organization classifies fosfomycin as critically important for human medicine.[12] It is available as a generic medication.[13] It was originally produced by certain types of Streptomyces, although it is now made chemically.[10]

Medical uses

[edit]

Fosfomycin is used to treat bladder infections as well as urinary tract infections (UTIs), where it is usually given as a single dose by mouth.[14]

Oral fosfomycin is not recommended for children under 12 years old.[15]

Additional uses have been proposed.[16] The global problem of advancing antimicrobial resistance has led to a renewed interest in its use more recently.[17]

Fosfomycin can be used as an efficacious treatment for both UTIs and complicated UTIs including acute pyelonephritis. The standard regimen for complicated UTIs is an oral 3 g dose administered once every 48 or 72 hours for a total of 3 doses or a 6 g dose every 8 hours for 7–14 days when fosfomycin is given in IV form.[18]

Intravenous fosfomycin is being increasingly used for treating infections caused by multidrug-resistant bacteria, mostly as a partner drug in order to avoid the occurrence of resistances and to take advantage of its synergistic activity with several other antimicrobials. In real-life settings, intravenous fosfomycin is most commonly used to treat pneumonia (34%), bloodstream infections (22%), and urinary tract infections (21%). In the majority of cases, it is administered in combination with a beta-lactam antibiotic, and in approximately half of the cases, it is employed as empirical therapy.[19][20] Daily adult dose usually ranges from 12 to 24 grams.[21] When administered in continuous infusion, a loading dose of fosfomycin 8 g followed by a daily dose of 16 g or 24 g. Continuous infusion is suggested in patients with normal renal function.[22]

Fosfomycin demonstrated strong antibiofilm activity in both in vitro and in vivo studies, including prosthetic material infections. It maintains antibiofilm activity against both Gram-positive (including MRSA) and Gram-negative bacteria.[23]

Bacterial sensitivity

[edit]

The fosfomycin molecule has an epoxide or oxirane ring, which is highly strained and thus very reactive.[citation needed]

Fosfomycin has broad antibacterial activity against both Gram-positive and Gram-negative pathogens, with useful activity against E. faecalis, E. coli, and various Gram-negatives such as Citrobacter and Proteus. Given a greater activity in a low-pH milieu, and predominant excretion in active form into the urine, fosfomycin has found use for the prophylaxis and treatment of UTIs caused by these uropathogens. Of note, activity against S. saprophyticus, Klebsiella, and Enterobacter is variable and should be confirmed by minimum inhibitory concentration testing. Activity against extended-spectrum β-lactamase-producing pathogens, notably ESBL-producing E. coli, is good to excellent, because the drug is not affected by cross-resistance issues. Existing clinical data support use in uncomplicated UTIs, caused by susceptible organisms. However, susceptibility break-points of 64 mg/L should not be applied for systemic infections.[citation needed]

Resistance

[edit]

Development of bacterial resistance under therapy is a frequent occurrence and makes fosfomycin unsuitable for sustained therapy of severe infections. Mutations that inactivate the nonessential glycerophosphate transporter render bacteria resistant to fosfomycin.[24][25][26] Still, fosfomycin can be used to treat MRSA bacteremia.[27]

Prescribing fosfomycin together with at least another active drug reduces the risk of developing bacterial resistance. Fosfomycin acts synergistically with many other antibiotics, including aminoglycosides, carbapenems, cephalosporins, daptomycin and oritavancin.[21][28]

Enzymes conferring resistance to fosfomycin have also been identified and are encoded both chromosomally and on plasmids.[29]

Three related fosfomycin resistance enzymes (named FosA, FosB, and FosX) are members of the glyoxalase superfamily. These enzymes function by nucleophilic attack on carbon 1 of fosfomycin, which opens the epoxide ring and renders the drug ineffective.[citation needed]

The enzymes differ by the identity of the nucleophile used in the reaction: glutathione for FosA, bacillithiol for FosB,[30][31] and water for FosX.[29]

In general, FosA and FosX enzymes are produced by Gram-negative bacteria, whereas FosB is produced by Gram-positive bacteria.[29]

FosC uses ATP and adds a phosphate group to fosfomycin, thus altering its properties and making the drug ineffective.[32]

Side effects

[edit]

The drug is well tolerated and has a low incidence of harmful side effects.[14]

Mechanism of action

[edit]

Despite its name (ending in -omycin) Fosfomycin is not a macrolide, but a member of a novel class of phosphonic antibiotics. Fosfomycin is bactericidal and inhibits bacterial cell wall biogenesis by inactivating the enzyme UDP-N-acetylglucosamine-3-enolpyruvyltransferase, also known as MurA.[33] This enzyme catalyzes the committed step in peptidoglycan biosynthesis, namely the ligation of phosphoenolpyruvate (PEP) to the 3'-hydroxyl group of UDP-N-acetylglucosamine. This pyruvate moiety provides the linker that bridges the glycan and peptide portion of peptidoglycan. Fosfomycin is a PEP analog that inhibits MurA by alkylating an active site cysteine residue (Cys 115 in the Escherichia coli enzyme).[34][35]

Fosfomycin enters the bacterial cell through the glycerophosphate transporter.[36]

Immunomodulatory properties

[edit]

Beyond its antibacterial activity, fosfomycin has been shown to modulate immune responses. Recent studies demonstrate that it can reduce the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), inhibit key inflammatory pathways such as NF-κB and MAPK, and increase anti-inflammatory mediators like IL-10. Additionally, fosfomycin may suppress T-cell proliferation, reduce neutrophil activation, and enhance tissue repair processes. These findings suggest potential applications in conditions involving dysregulated inflammation, such as sepsis or chronic wounds.[37]

History

[edit]

Fosfomycin (originally known as phosphonomycin) was discovered in a joint effort of Merck and Co. and Spain's Compañía Española de Penicilina y Antibióticos (CEPA). It was first isolated by screening broth cultures of Streptomyces fradiae isolated from soil samples for the ability to cause formation of spheroplasts by growing bacteria. The discovery was described in a series of papers published in 1969.[38] CEPA began producing fosfomycin on an industrial scale in 1971 at its Aranjuez facility.[39]

Biosynthesis

[edit]

The complete fosfomycin biosynthetic gene cluster from Streptomyces fradiae has been cloned and sequenced and the heterologous production of fosfomycin in S. lividans has been achieved by Ryan Woodyer of the Huimin Zhao and Wilfred van der Donk research groups.[40]

Synthetic manufacture

[edit]

Large scale production of fosfomycin is achieved by making an epoxide of cis-propenylphosphonic acid to yield racemic mixture fosfomycin.[41]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Fosfomycin

View on Grokipedia
from Grokipedia
Fosfomycin is a broad-spectrum, bactericidal that acts by inhibiting the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), disrupting the early stages of bacterial synthesis essential for formation. Originally discovered in from fermentation products of fradiae by researchers at the Spanish Penicillin and Antibiotics Company, it is now produced both naturally and synthetically, and is notable for its low molecular weight, which allows rapid absorption and tissue penetration. Clinically, fosfomycin is primarily indicated for the treatment of uncomplicated urinary tract infections (UTIs), such as cystitis in women, where it is administered as a single 3-gram oral dose of fosfomycin tromethamine granules dissolved in water, offering high efficacy against pathogens like and . An intravenous formulation, approved for complicated UTIs including acute caused by or , is dosed at 6 grams every 8 hours for up to 14 days, with adjustments for renal impairment. Its activity extends to multidrug-resistant (MDR) and extensively drug-resistant (XDR) , including extended-spectrum (ESBL)-producing and methicillin-resistant Staphylococcus aureus (MRSA), making it valuable for off-label uses in conditions like , , and prophylaxis for procedures such as prostate biopsies, often in combination therapy. Fosfomycin exhibits a broad antibacterial spectrum against many Gram-positive and Gram-negative aerobes but is ineffective against anaerobes, Pseudomonas aeruginosa, and Acinetobacter species due to inherent resistance or poor uptake. Resistance can emerge through mutations in transport systems (e.g., glpT or uhpT genes) or acquisition of modifying enzymes like FosA or FosB, though rates remain relatively low in clinical settings. Pharmacologically, it achieves peak urinary concentrations exceeding 1000 μg/mL after oral dosing, with a half-life of about 5.7 hours and primarily renal excretion unchanged, and minimal protein binding. Common side effects of oral fosfomycin include , , , and vaginal yeast infections, while intravenous use may additionally cause , elevated liver enzymes, or sodium overload; severe reactions such as or Clostridioides difficile-associated are rare but require immediate medical attention. It is generally well-tolerated, with contraindications limited to , and precautions advised in patients with or during and due to limited data.

Chemistry

Chemical structure

Fosfomycin is a low-molecular-weight phosphonic acid derivative characterized by the molecular formula \ceC3H7O4P\ce{C3H7O4P} and a monoisotopic mass of 138.008195 Da. Its core structure consists of an (oxirane) ring attached to a phosphono group via a propyl chain, which confers unique reactivity and enables it to mimic the natural substrate phosphoenolpyruvate (PEP) in bacterial enzymatic processes. This structural feature positions the phosphono moiety in a configuration that parallels the enolpyruvate portion of PEP, highlighting fosfomycin's classification as a PEP analog. The biologically active enantiomer of fosfomycin is the (2R,3S)-epoxypropylphosphonic acid, systematically named [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid. In this configuration, the oxirane ring bears a methyl group at the 3-position, with the phosphonic acid group linked to the 2-position, forming a compact, three-membered ring that is strained and electrophilic at the epoxide carbons. This arrangement not only defines its stereochemistry but also underpins its antibiotic properties through covalent modification potential. The molecule's overall simplicity, with just three carbon atoms, contributes to its broad-spectrum activity and favorable pharmacokinetic profile. Fosfomycin's phosphono- scaffold also exhibits structural analogies to glycerol-3- (G3P) and glucose-6- (G6P), particularly in the positioning of the -like group and the hydroxyl-mimicking , which facilitate uptake via bacterial transporters such as GlpT and UhpT. These resemblances allow fosfomycin to exploit existing transport systems without requiring dedicated uptake mechanisms. Commercially, fosfomycin is formulated as salts to enhance and for different administration routes: fosfomycin tromethamine, a water-soluble salt used for oral therapy; fosfomycin disodium, suitable for intravenous infusion; and fosfomycin calcium, an earlier oral form now less commonly used due to inferior absorption compared to the tromethamine salt. These salt forms maintain the core epoxypropylphosphonic acid structure while altering physical properties for clinical application.

Physical and chemical properties

Fosfomycin is typically obtained as a white crystalline powder in its free acid or salt forms, such as the sodium or tromethamine salts. The compound has a of 94–95 °C, at which it decomposes without boiling. Fosfomycin demonstrates high in , with the free acid soluble at approximately 47 g/L at 25 °C, while its salts exhibit even greater solubility; for instance, the disodium salt is very soluble (>100 g/L), and the tromethamine salt is freely soluble in (around 50 g/100 mL). In contrast, it shows low solubility in organic solvents, being sparingly soluble in and practically insoluble in , acetone, and . The phosphonic acid moiety of fosfomycin has pKa values of approximately 2.5 (first dissociation) and 6.7 (second dissociation), influencing its ionization and reactivity in different environments. Fosfomycin is chemically stable in acidic media but sensitive to alkaline conditions, where the strained ring undergoes ring-opening , and to elevated temperatures that accelerate decomposition. Pharmaceutical formulations, such as oral granules or intravenous solutions, maintain stability with a shelf-life of 2–3 years when stored at (15–30 °C) in dry conditions. As a chiral molecule, the biologically active (2R,3S)-enantiomer of fosfomycin exhibits optical activity, with a specific rotation of –13° to –15° (c=5% in water).

Pharmacology

Mechanism of action

Fosfomycin exerts its antibacterial effect by inhibiting UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), the enzyme catalyzing the first committed step in peptidoglycan biosynthesis, a critical process for bacterial cell wall formation. This inhibition occurs through competitive mimicry of the substrate phosphoenolpyruvyl transferase (PEP), where fosfomycin binds covalently to the active site cysteine residue (Cys115 in Escherichia coli) via nucleophilic attack and subsequent epoxide ring opening, irreversibly inactivating the enzyme and preventing the transfer of the enolpyruvyl moiety to UDP-N-acetylglucosamine. The MurA active site is highly conserved across bacterial species, contributing to fosfomycin's broad-spectrum activity against both Gram-positive and Gram-negative pathogens. Entry into bacterial cells is facilitated by specific transporters: in , primarily via the glycerol-3-phosphate transporter (GlpT) or the hexose phosphate transporter (UhpT), with GlpT being more widespread across species. In , uptake occurs through chromosomally encoded transporters, such as glycerol uptake systems exemplified by GlpT homologs in . Once inside the , fosfomycin's irreversible binding to MurA disrupts precursor synthesis, leading to weakened cell walls and eventual bacterial lysis. The inhibition is bactericidal, causing disruption that is effective against both actively dividing and non-dividing , as maintenance is a universal requirement for bacterial viability regardless of growth phase. This time-dependent action underscores fosfomycin's utility in targeting persistent or biofilm-associated infections where bacterial may be reduced.

Pharmacokinetics

Fosfomycin exhibits favorable pharmacokinetic properties across various administration routes, primarily due to its low molecular weight and hydrophilic nature. When administered orally as the tromethamine salt, fosfomycin demonstrates a of 34-58% under conditions, which decreases to approximately 30% when taken with food. A single 3 g oral dose results in rapid absorption from the , achieving peak urinary concentrations exceeding 1000 mg/L, with levels remaining above 100 mg/L for 48-72 hours, supporting its use in single-dose regimens for urinary tract infections; the elimination is approximately 5.7 hours. Intravenous administration of fosfomycin provides 100% , with peak plasma concentrations of 200-400 mg/L observed following doses of 4-8 g. The elimination for intravenous administration in healthy adults is approximately 2.5 hours, though it prolongs significantly in patients with renal impairment, necessitating careful monitoring. Distribution of fosfomycin is characterized by low (<5%) and a volume of distribution of 0.2-0.3 L/kg, indicating moderate penetration into extracellular fluids. It achieves good tissue concentrations in key sites such as urine, prostate, and bone, facilitating efficacy against localized infections. Metabolism of fosfomycin is minimal, with no significant involvement of hepatic cytochrome P450 enzymes. The drug is primarily excreted unchanged in the urine through a combination of glomerular filtration and tubular secretion; for intravenous administration, approximately 93% is recovered in urine, while for oral administration, approximately 38% is recovered in urine and 18% in feces. Renal clearance correlates closely with creatinine clearance, and population pharmacokinetic models highlight the influence of body weight and renal function on dosing requirements. Dosing adjustments are recommended for patients with creatinine clearance below 50 mL/min, such as dose reduction or extended intervals, to avoid accumulation.

Medical uses

Indications

Fosfomycin is primarily indicated for the treatment of uncomplicated urinary tract infections (uUTIs), specifically acute cystitis, in women aged 18 years and older due to susceptible strains of Escherichia coli and Enterococcus faecalis. The recommended regimen is a single 3-gram oral dose of fosfomycin tromethamine. In 2025, the U.S. Food and Drug Administration (FDA) approved intravenous (IV) fosfomycin (Contepo) for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis, in adults aged 18 years and older caused by susceptible isolates of E. coli or Klebsiella pneumoniae. The standard dosing for patients with creatinine clearance greater than 50 mL/min is 6 grams IV every 8 hours, infused over 1 hour, for a duration of 7 to 14 days depending on clinical response. Dosage adjustments are required for renal impairment to maintain efficacy and safety. Off-label uses of fosfomycin include the management of multidrug-resistant (MDR) infections beyond the urinary tract, such as osteomyelitis, prostatitis, and sepsis, often in combination with other antimicrobials to enhance efficacy against pathogens like extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. Clinical success rates for these applications are moderate, particularly when fosfomycin is used adjunctively in polymicrobial or resistant cases. Fosfomycin is not recommended for upper urinary tract infections, such as , when using the oral formulation due to inadequate tissue concentrations; IV administration is preferred in such scenarios. Oral fosfomycin should not be used in children under 12 years of age, and IV fosfomycin's safety and efficacy have not been established in patients younger than 18 years. It is also not advised for systemic infections without microbiologic confirmation of susceptibility to avoid promoting resistance. Fosfomycin has been included on the World Health Organization's Model List of Essential Medicines since 2019, recognizing its role in treating common bacterial infections in resource-limited settings. Recent evidence from the ZEUS phase 2/3 trial supports its use in cUTIs, demonstrating noninferiority to piperacillin-tazobactam with an overall success rate of 63.5% in the microbiological intent-to-treat population.

Bacterial susceptibility

Fosfomycin demonstrates broad-spectrum in vitro antibacterial activity against a range of Gram-positive and Gram-negative bacteria, primarily through inhibition of cell wall synthesis via the conserved enzyme MurA across species. It exhibits potent activity against many Gram-positive pathogens, including Staphylococcus aureus (both methicillin-susceptible and methicillin-resistant strains) and Enterococcus spp., where MIC90 values for susceptible isolates are typically ≤4 mg/L. Susceptibility rates exceed 90% for S. aureus isolates in contemporary surveillance studies, with similar efficacy observed against Enterococcus faecalis, though activity against E. faecium can be more variable. Against , fosfomycin is highly effective against , with MIC90 values of 1–4 mg/L for susceptible strains, and shows moderate activity against other such as , where MIC90 ranges from 1–8 mg/L in susceptible populations. It retains activity against many multidrug-resistant (MDR) strains within these groups, particularly extended-spectrum β-lactamase (ESBL)-producing . Fosfomycin also displays activity against certain anaerobes, such as spp. (MIC90 ≤32 mg/L), and some atypical pathogens including , though it lacks reliable activity against spp. and , where MIC values often exceed 128 mg/L, rendering most strains inherently resistant. Fosfomycin often exhibits synergistic effects when combined with β-lactams, enhancing activity against MDR ; for instance, combinations with or cephalosporins lower MICs by 2–4 dilutions for ESBL- and carbapenem-resistant strains. Clinical Laboratory Standards Institute (CLSI) and European Committee on Susceptibility Testing (EUCAST) breakpoints for define susceptibility as MIC ≤64 mg/L for oral formulations and ≤16 mg/L for intravenous use, with similar thresholds applied to Staphylococcus spp. and Enterococcus faecalis. Susceptibility testing for fosfomycin is recommended via dilution methods due to the compound's in assays, which can lead to falsely elevated MICs; supplementation with glucose-6-phosphate (25 mg/L) in Mueller-Hinton is standard to facilitate and ensure accurate results.
Bacterial GroupRepresentative PathogensTypical MIC90 for Susceptible Strains (mg/L)Source
Gram-positive, ≤4CMR Review
Gram-negative, (susceptible)1–8CMR Review
Anaerobes spp.≤32PubMed 583867
Pseudomonas>128CMR Review

Resistance

Bacterial resistance to fosfomycin can arise through several mechanisms that impair drug entry, alter the target enzyme, inactivate the antibiotic, or enhance its expulsion from the cell. These mechanisms have significant genetic and clinical implications, particularly in treating infections caused by Enterobacterales and other Gram-negative pathogens. One primary mechanism involves reduced uptake of fosfomycin into bacterial cells. In Escherichia coli and other Enterobacterales, mutations in the glpT gene, which encodes the glycerol-3-phosphate permease, or the uhpT gene, responsible for the hexose-phosphate uptake system, significantly decrease fosfomycin transport across the inner membrane. The glpT transporter is broadly utilized among many bacteria, while uhpT is more restricted to Enterobacteriaceae and Staphylococcus aureus. In Gram-negative bacteria such as Pseudomonas aeruginosa, loss of outer membrane porins further limits permeability, compounding the effect of inner membrane transporter defects. Target modification represents another key resistance strategy, primarily affecting the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), fosfomycin's site of action. Point in the murA gene, such as the C115D substitution in E. coli, alter the residue critical for fosfomycin binding, thereby preventing irreversible inhibition of synthesis. These are relatively rare in clinical isolates but can confer high-level resistance when present. Enzymatic inactivation of fosfomycin occurs via plasmid- or chromosomally encoded enzymes that open the antibiotic's epoxide ring. In Enterobacterales, FosA, a glutathione S-transferase, catalyzes the addition of glutathione to the epoxide, rendering the drug inactive; variants like plasmid-borne fosA3 are increasingly reported, with up to 80% of resistant E. coli isolates in certain regions carrying this gene. In Gram-positive bacteria like staphylococci, FosB, a bacillithiol S-transferase, performs a similar function using bacillithiol as the thiol donor in the presence of magnesium ions. These enzymes are often acquired horizontally, facilitating spread among pathogens. Efflux pumps contribute to resistance by actively exporting fosfomycin from the bacterial cytoplasm. Overexpression of these pumps is particularly noted in Pseudomonas aeruginosa and Acinetobacter baumannii, where systems like MexAB-OprM in P. aeruginosa and the major facilitator superfamily transporter AbaF in A. baumannii reduce intracellular drug concentrations, often in combination with uptake defects. Clinically, fosfomycin resistance prevalence remains low in uncomplicated urinary tract infections (uUTIs) caused by E. coli, typically ranging from 1% to 10%, with rates as low as 0.7%–2% reported in European and Turkish surveillance studies. However, resistance is higher in multidrug-resistant (MDR) strains, reaching up to 30% in extended-spectrum β-lactamase (ESBL)-producing or carbapenemase-producing isolates, such as 21.6% in and 13% overall in ESBL . Co-selection pressures from other antibiotics exacerbate this, as resistance genes like fosA3 are frequently co-located on plasmids with carbapenemase genes such as blaKPC-2, promoting dissemination in hospital settings. Detection of fosfomycin resistance poses challenges, as phenotypic methods like disk diffusion are unreliable, often overcalling resistance due to inconsistent zone interpretations, particularly in . More accurate phenotypic assessment relies on or agar dilution with glucose-6-phosphate supplementation, using breakpoints such as susceptible ≤32 mg/L per EUCAST guidelines. Genotypic detection via PCR targeting fosA and fosB genes is increasingly used to identify enzymatic inactivation mechanisms, enabling rapid screening in high-risk populations.

Adverse effects

Common side effects

Fosfomycin, particularly in its oral formulation as a single-dose treatment for uncomplicated urinary tract infections, is generally well tolerated, with common side effects primarily affecting the gastrointestinal system and occurring in 10-20% of patients across clinical trials. The most frequent adverse reaction is , reported in approximately 9-10% of cases, often attributed to the drug's partial absorption and resulting osmotic effects in the gut lumen. Other gastrointestinal issues include (4-5%), abdominal pain (2-3.5%), and dyspepsia (2-3%), which are typically mild and transient. Neurological effects such as (approximately 9-10%) and (2-5%) are also commonly observed but self-limiting. In women, or yeast infections occur in 5-8% of cases, likely due to disruption of following exposure. These side effects arise mainly from the single-dose and do not usually require intervention beyond supportive care, such as hydration, with most resolving within 24-48 hours.

Serious adverse effects

Serious adverse effects of fosfomycin are infrequent but can include life-threatening reactions such as and anaphylactic shock, occurring at an unknown frequency based on available data. These reactions may manifest as or pruritus in more severe cases, though milder dermatologic symptoms are more common; with other antibiotics, including beta-lactams like penicillins, is low due to fosfomycin's distinct . Fosfomycin is contraindicated in patients with a history of serious to the drug or its excipients, and treatment should be discontinued immediately if signs of appear. Hepatobiliary disorders represent another rare serious risk, with elevated liver enzymes reported in approximately 2% of patients receiving parenteral fosfomycin in clinical trials, though rates up to 10.3% for or aspartate aminotransferase elevations greater than three times the upper limit of normal have been observed in more recent intravenous formulations. and clinically apparent , including cholestatic or hepatocellular patterns, are exceptionally uncommon, with only a handful of case reports documenting onset within one week of administration and resolution upon discontinuation. These events are typically and reversible but underscore the need for liver function monitoring during prolonged intravenous use. Serious effects also include -associated pseudomembranous , reported at a frequency of less than 0.1% based on post-marketing surveillance data, though the exact incidence remains unknown and can range from mild to fatal . has been noted in cases of high dosing or sodium overload, particularly with intravenous administration, but occurs infrequently in standard dosing. For intravenous fosfomycin, electrolyte disturbances such as (9.9% incidence in clinical trials) and (3.4%) are significant risks due to the high sodium content (1,980 mg per ), potentially leading to imbalances in sodium, , calcium, and levels; monitoring of serum electrolytes and fluid status is recommended. Other serious adverse effects encompass hematologic issues such as , observed in 1% to 6.4% of patients in parenteral trials and potentially progressing to in post-marketing reports, necessitating monitoring. is rare, with an incidence of about 0.7% in studies and isolated case reports of . For intravenous fosfomycin, phlebitis at the infusion site occurs in approximately 1% of cases, though higher rates up to 25% have been reported in small crossover studies with continuous . Post-marketing surveillance through 2025, including analyses of the FDA Reporting System database and large cohort studies, confirms a low overall incidence of serious adverse effects at less than 1%, with and hematologic events among the most frequently signaled in disproportionality assessments. In a nationwide prospective study of over 100,000 intravenous cases, serious reactions like anaphylactic shock occurred in only 0.004%.

Veterinary uses

Applications

In , fosfomycin is primarily used to treat bacterial urinary tract infections (UTIs) in dogs caused by multidrug-resistant . It serves as an alternative therapy when standard antibiotics fail, leveraging its broad-spectrum activity against Gram-negative pathogens. Fosfomycin is contraindicated in cats due to the risk of . For livestock, fosfomycin addresses respiratory and gastrointestinal infections in broiler chickens and pigs, targeting E. coli and Salmonella species. In broilers, it is administered to control colibacillosis and salmonellosis outbreaks, while in pigs, it treats similar enteric and respiratory conditions. Dosing regimens vary by species: in dogs, an oral dose of 40 mg/kg body weight every 12 hours is recommended for UTIs, often for 3–5 days. In poultry, doses range from 100–200 mg/kg body weight, typically delivered via medicated feed or drinking water for 3–5 consecutive days. Fosfomycin is not centrally authorized for veterinary use in the (categorized as reserved for human medicine) but has been used in some member states for bacterial infections in chickens and pigs, often off-label or under national provisions. In companion animals, its application remains off-label, reserved for cases involving multidrug-resistant pathogens where few alternatives exist. Key advantages include its potential for single-dose efficacy in some protocols due to favorable and rapid tissue elimination, with residues clearing from animal tissues within 2–3 days, minimizing concerns. Recent studies from 2020–2023 have demonstrated pharmacokinetic analyses supporting fosfomycin's use for systemic infections in horses.

Resistance considerations

Resistance to fosfomycin in veterinary settings is an emerging concern, particularly in where prevalence rates are increasing due to selective pressures from use. In pigs, fosfomycin resistance among Salmonella isolates stands at approximately 15.6% globally, rising to 24.7% in Asian populations, driven by the dissemination of the fosA gene on . This trend reflects broader patterns in food animals, with resistance rates also elevated in chickens (10.5% globally, up to 33.5% in ) and turkeys (15.5%). In contrast, resistance remains lower in companion animals, with Escherichia coli isolates from dogs and cats showing rates of 1.1% in the and 10.2% in , generally falling within 5-15% across studied regions. The primary mechanisms of fosfomycin resistance in veterinary pathogens mirror those observed in human isolates, involving enzymatic inactivation and reduced drug uptake. Key enzymes include FosA and FosB metalloenzymes, which modify fosfomycin by opening its epoxide ring using cofactors like glutathione or bacillithiol, rendering it inactive; fosA variants such as fosA3 are commonly plasmid-borne in E. coli and Salmonella from animals. Additionally, mutations in uptake transporters like GlpT (glycerol-3-phosphate permease) or UhpT (hexose phosphate transporter) limit intracellular accumulation of the antibiotic, conferring low- to moderate-level resistance with frequencies around 10⁻⁷ to 10⁻⁸ in E. coli. Co-selection plays a significant role in veterinary contexts, as agricultural antibiotic use—particularly of β-lactams and other classes—promotes the horizontal transfer of plasmids carrying fosA3 alongside genes like blaCTX-M, enhancing multidrug resistance in livestock pathogens such as E. coli from pigs and poultry. Ongoing monitoring highlights the need for vigilance, with global data indicating rising minimum inhibitory concentrations (MICs) for fosfomycin in poultry-associated Salmonella and E. coli over the past three decades, particularly in high-production regions. For multidrug-resistant (MDR) strains, is recommended to restore , pairing fosfomycin with β-lactams, aminoglycosides, or polymyxins to exploit synergistic effects and overcome resistance barriers in animal infections. To mitigate residues, withdrawal periods of 5 days for eggs and 10 days for meat are advised following oral administration in , ensuring compliance. Recent studies underscore zoonotic risks, with 2023 analyses revealing plasmid-mediated transfer of fosA3 resistance from waterfowl E. coli to potential human pathogens via conjugative elements, at transfer frequencies up to 1.1 × 10⁻¹, emphasizing the one-health implications of veterinary resistance dissemination.

History

Discovery

Fosfomycin, originally named phosphonomycin, was discovered in through a collaborative effort between researchers at the Spanish company Compañía Española de Penicilina y Antibióticos (CEPA) and Merck Sharp & Dohme (MSD) in the United States. The antibiotic was isolated from fermentation broths of the bacterium fradiae (ATCC 21096), which had been identified in a soil sample collected from Mount Montgó in , . Early characterization revealed fosfomycin's broad-spectrum bactericidal activity against both Gram-positive and in laboratory tests conducted in 1969 and 1970. In vitro assays demonstrated inhibition of pathogens such as , , and species at low concentrations, while studies in mice confirmed efficacy against systemic infections when administered orally. The initial isolation and structural elucidation were detailed in a seminal 1969 publication by Hendlin and colleagues, marking the first description of this epoxide-containing phosphonic acid . Subsequent studies in the early 1970s identified fosfomycin production in other bacteria, including , expanding understanding of its natural occurrence.

Development and approvals

Following its discovery in 1969, fosfomycin entered industrial production in in 1971 through Compañía Española de Penicilina y Antibióticos (CEPA), marking the transition from laboratory synthesis to commercial scale manufacturing. Concurrently, production ramped up in , where early clinical studies supported its adoption for bacterial infections, leading to widespread use in by the mid-1970s. The oral formulation, fosfomycin tromethamine, received approvals across several European countries in the early 1970s, initially for intravenous administration of the disodium salt in treating urinary tract and other infections, establishing it as a key in regions like and . In the United States, the (FDA) approved fosfomycin tromethamine (branded as Monurol) in December 1996 as a single 3-gram oral dose for uncomplicated urinary tract infections (uUTIs) in women, based on clinical trials demonstrating high efficacy against common pathogens like . During the , the intravenous disodium form gained traction off-label for managing multidrug-resistant (MDR) infections, particularly in hospital settings where options were limited, though it remained unavailable as a commercial product in the US. This period also saw fosfomycin's inclusion on the World Health Organization's Model List of in 2017 (injection form), recognizing its role in treating resistant bacterial infections globally. The 2010s marked a revival of interest in fosfomycin amid rising antimicrobial resistance, with numerous studies highlighting its efficacy against MDR Gram-negative bacteria, including extended-spectrum β-lactamase producers, in both oral and intravenous forms for complicated infections. In the European Union, approvals expanded to veterinary applications in several member states during this decade, permitting its use for bacterial infections in broiler chickens and pigs to address zoonotic resistance concerns. Building on this momentum, the FDA approved intravenous fosfomycin (Contepo) on October 22, 2025, for complicated urinary tract infections (cUTIs), including pyelonephritis, in adults with limited treatment options; this milestone was supported by the phase 2/3 ZEUS trial, which demonstrated noninferiority to piperacillin/tazobactam, with 63.5% overall success in microbiological intent-to-treat analysis. Fosfomycin is now available as a generic in numerous countries across , , and , facilitating broader access for uUTIs and select systemic infections. However, in low-resource settings, challenges persist due to variable supply chains, higher costs relative to first-line alternatives, and limited intravenous formulations, hindering equitable global distribution despite its essential status.

Production

Biosynthesis

Fosfomycin is biosynthesized by certain bacteria, including Streptomyces fradiae and Pseudomonas syringae, as a secondary metabolite via distinct pathways that originate from phosphoenolpyruvate (PEP). In S. fradiae, the process follows a seven-step enzymatic pathway that establishes the characteristic C-P bond and epoxide ring of the molecule. This pathway has been elucidated through genetic and biochemical studies, including heterologous expression systems. The pathway begins with the isomerization of PEP to phosphonopyruvate (PnPy) catalyzed by the phosphoenolpyruvate mutase activity of the bifunctional Fom1, encoded by the fom1 . Next, PnPy undergoes to form phosphonoacetaldehyde, mediated by Fom2 (fom2 ), a β-keto acid decarboxylase. This intermediate is then reduced to 2-hydroxyethylphosphonate (HEP) by a phosphonoacetaldehyde reductase. Chain extension occurs in subsequent steps: HEP is first activated as a cytidylyl intermediate (HEP-CMP) by a nucleotidyltransferase, followed by to hydroxypropylphosphonate-CMP (HPP-CMP) via the radical SAM Fom3 (fom3 ), which requires S-adenosylmethionine (SAM) and methylcobalamin (MeCbl) to generate a 5'-deoxyadenosyl radical for stereospecific methyl transfer. Deactivation by a yields (S)-2-hydroxypropylphosphonate (2-HPP), which is then converted to fosfomycin through epoxide formation by the P450-like epoxidase Fom4 (fom4 ), utilizing as the oxidant. The biosynthetic gene cluster in S. fradiae spans approximately 35 kb and includes the core fom genes (fom1 to fom4, fomA to fomD), along with regulatory elements such as the LuxR-type activator FomR. Heterologous expression of the minimal cluster in Streptomyces lividans has enabled detailed enzymatic characterization and confirmation of the pathway, resulting in fosfomycin production. In contrast, the pathway in P. syringae diverges after PnPy formation, employing a citrate synthase-like enzyme (Psf2) for acetylation and subsequent steps involving oxidative decarboxylation by a diiron metallohydrolase (PsfC) to generate key intermediates like 2-oxopropylphosphonate before converging at 2-HPP and epoxidation. This variant lacks the direct decarboxylation and cytidylylation seen in Streptomyces, reflecting evolutionary adaptations in phosphonate metabolism. Production yields in S. fradiae can be enhanced through medium optimization, with glucose-asparagine-based formulations supplemented by L-methionine, L-glutamate, and citrate promoting accumulation by supporting precursor availability and reducing . These conditions have been shown to increase fosfomycin titers significantly compared to basal media.

Chemical synthesis

The primary method for synthesizing fosfomycin involves the epoxidation of cis-propenylphosphonic acid (also known as (Z)-1-propenylphosphonic acid) to produce a racemic mixture of the epoxide, followed by resolution to isolate the active (1R,2S)-enantiomer. This approach, first reported in 1969, utilizes peracid epoxidation under controlled conditions to achieve stereospecific ring closure, with yields improved to around 81% through the use of protecting groups such as tert-butyl esters. Resolution of the racemate is typically achieved through methods like preferential crystallization with chiral resolving agents or enzymatic processes, such as hydrolysis using specific hydrolases to selectively degrade the inactive enantiomer, enabling recovery of the desired (S)-configuration with high optical purity. A more , non-chloride route has been developed using of (E)-1-propenylphosphonate with AD-mix-α, followed by ring closure to form the . This method, emphasizing reduced waste and avoidance of toxic reagents, proceeds via osmium-catalyzed to yield the (1S,2S)-dihydroxy intermediate in 65% yield and >99% enantiomeric excess, which is then converted to fosfomycin through base-mediated formation. This approach aligns with sustainable synthesis principles by minimizing hazardous solvents and catalysts, making it suitable for scalable production without chloride-based intermediates. An alternative synthetic pathway starts from glycerol derivatives, such as protected 1,2-propanediol phosphonates, leading to dihydroxyphosphonic intermediates that undergo esterification to form the tromethamine salt of fosfomycin. In this route, -based starting materials are phosphorylated and oxidized to generate the 1,2-dihydroxypropylphosphonate core, which is then selectively esterified with tromethamine under mild conditions to yield the water-soluble salt with good efficiency. On an industrial scale, processes like the one originally developed by Merck achieve fosfomycin production with greater than 90% purity while avoiding heavy metal catalysts, relying instead on organic peracids or metal-free epoxidants for the key ring formation step. These methods prioritize cost-effective, high-throughput operations, often incorporating in-line purification to meet pharmaceutical standards. Key challenges in fosfomycin synthesis include achieving high for the biologically active (S)-, as racemic mixtures require additional resolution steps that can reduce overall yield. Recent patents, such as CN104086592A, address this by optimizing the preparation of the tromethamine salt through efficient esterification of resolved intermediates, improving scalability and purity for clinical formulations.

References

  1. https://go.drugbank.com/drugs/DB00828
  2. https://journals.asm.org/doi/10.1128/cmr.00068-15
  3. https://www.mayoclinic.org/drugs-supplements/fosfomycin-oral-route/description/drg-20063920
  4. https://www.drugs.com/fosfomycin.html
  5. https://pubchem.ncbi.nlm.nih.gov/compound/Fosfomycin
  6. https://www.mdpi.com/1422-0067/23/1/159
  7. https://www.chemspider.com/Chemical-Structure.394204.html
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC9088020/
  9. https://jpdb.nihs.go.jp/jp14e/14data/Part-I/Fosfomycin_Sodium.pdf
  10. https://toku-e.com/fosfomycin-tromethamine/
  11. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9365184.htm
  12. https://www.tga.gov.au/sites/default/files/auspar-fosfomycin-trometamol-180907.pdf
  13. https://www.researchgate.net/figure/The-Fosfomycin-behavior-in-a-acidic-medium-and-b-alkaline-medium_fig8_360227774
  14. https://www.sciencedirect.com/science/article/abs/pii/S0167732220320778
  15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050717s005lbl.pdf
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC10537177/
  17. https://toku-e.com/fosfomycin-sodium/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC5287057/
  19. https://doi.org/10.1111/j.1749-6632.1974.tb43277.x
  20. https://doi.org/10.1021/bi00201a011
  21. https://doi.org/10.1074/jbc.M409252200
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC6555162/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3855495/
  24. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050717s009lbl.pdf
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC5571362/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC6555163/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4576076/
  28. https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Fosfomycin_MONUROL_criteria_for_use_Jan_2023.pdf
  29. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212271s000lbl.pdf
  30. https://www.urologytimes.com/view/fda-approves-fosfomycin-for-complicated-urinary-tract-infections
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC10241401/
  32. https://www.idstewardship.com/drugs/fosfomycin/
  33. https://pch.health.wa.gov.au/~/media/Files/Hospitals/PCH/General-documents/Health-professionals/ChAMP-Monographs/Fosfomycin.pdf
  34. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2019.06
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4786888/
  36. https://pubmed.ncbi.nlm.nih.gov/35476672/
  37. https://pubmed.ncbi.nlm.nih.gov/583867/
  38. https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/antimicrobial-dosing-protocols/SHC-Fosfomycin-Tip-Sheet.pdf
  39. https://www.eucast.org/bacteria/guidance-documents/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC11019110/
  41. https://academic.oup.com/jac/article/72/1/68/2643136
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10985827/
  43. https://www.mdpi.com/2079-6382/11/10/1383
  44. https://academic.oup.com/jac/article/73/9/2380/5047839
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC9411916/
  46. https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-annex-iii_en.pdf
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC4675770/
  48. https://www.researchgate.net/publication/287277528_Cross-reactivity_of_fosfomycin_to_b-lactams_-_Compared_in_the_response_of_guinea_pig_delayed_type_hypersensitivity
  49. https://www.ncbi.nlm.nih.gov/books/NBK547912/
  50. https://www.researchgate.net/publication/346366464_Clinical_Pharmacokinetics_of_Fosfomycin_after_Continuous_Infusion_Compared_with_Intermittent_Infusion_a_Randomized_Crossover_Study_in_Healthy_Volunteers
  51. https://pubmed.ncbi.nlm.nih.gov/40010731/
  52. https://www.researchgate.net/publication/285957393_A_post-marketing_surveillance_study_of_fosfomycin_sodium_for_injection_-_A_nationwide_prospective_study_of_safety_in_100000_cases
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC11240368/
  54. https://www.sciencedirect.com/science/article/abs/pii/S0378113510005122
  55. https://vcahospitals.com/know-your-pet/fosfomycin
  56. https://www.vdl.ndsu.edu/wp-content/uploads/2022/02/ISCAID-Urinary-Guidelines-2019.pdf
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC4629597/
  58. https://www.openveterinaryjournal.com/index.php?mno=302656846
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC10303435/
  60. https://www.dufafeed.com/wp-content/uploads/2017/03/DUFAPHOS-T_WSP.pdf
  61. https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-european-union-answer-request-european-commission-updating-scientific-advice-impact-public-health-animal-health-use-antibiotics-animals_en.pdf
  62. https://www.fao.org/faoterm/viewentry/en/?entryId=175085
  63. https://www.mdpi.com/2306-7381/10/5/337
  64. https://www.dvm360.com/view/antimicrobials-and-utis-part-2-antimicrobial-options-proceedings
  65. https://www.mdpi.com/2079-6382/13/8/713
  66. https://www.nature.com/articles/s41467-025-59758-3
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC10223593/
  68. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2023.1178547/full
  69. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1702881/full
  70. https://www.advacarepharma.com/en/veterinary/fosfomycin-oral-solution
  71. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1481822/full
  72. https://www.science.org/doi/10.1126/science.166.3901.122
  73. https://pubmed.ncbi.nlm.nih.gov/5809587/
  74. https://www.pnas.org/doi/10.1073/pnas.2019863118
  75. https://epmonthly.com/article/fosfomycin-monurol/
  76. https://pubmed.ncbi.nlm.nih.gov/832522/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC4833629/
  78. https://www.sciencedirect.com/science/article/pii/S1201971211001664
  79. https://list.essentialmeds.org/recommendations/714
  80. https://www.ema.europa.eu/en/news/recommendations-restrict-use-fosfomycin-antibiotics
  81. https://www.who.int/news/item/06-06-2017-who-updates-essential-medicines-list-with-new-advice-on-use-of-antibiotics-and-adds-medicines-for-hepatitis-c-hiv-tuberculosis-and-cancer
  82. https://pubs.rsc.org/en/content/articlehtml/2019/ra/c9ra08299a
  83. https://doi.org/10.1016/j.chembiol.2006.09.007
  84. https://zhaogroup.chbe.illinois.edu/publications/HZ54.pdf
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC3421606/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC428933/
  87. https://doi.org/10.1039/c9ra08299a
  88. https://www.sciencedirect.com/science/article/abs/pii/S1001841708003379
  89. https://patents.google.com/patent/EP0299484A1/en
  90. https://patents.google.com/patent/CN104086592A/en
Add your contribution
Related Hubs
User Avatar
No comments yet.